Secretome
  • Home
  • Leadership
  • News and Publications
    • News
    • Publications
Select Page

Neoprogen is now Secretome Therapeutics, in alignment with the company’s focus in revolutionizing cell therapy via neonatal cardiac progenitor cells (nCPCs) and their respective secretomes 

by secretome | Jun 1, 2023 | Investors, News, Uncategorized

Secretome Therapeutics Announces Appointment of Angela Shen, M.D., M.B.A., to Board of Directors

by secretome | Oct 4, 2022 | News, Uncategorized

Secretome Therapeutics, a preclinical company developing novel therapies derived from neonatal mesenchymal stem cells, today announced the appointment of Angela Shen, M.D., M.B.A, to its Board of Directors. Dr. Shen is currently the Vice President, Strategic...

Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury

by Sudhish Sharma | Jun 17, 2022 | Journals, Uncategorized

Abstract Gunasekaran et al demonstrate that human neonatal Mesenchymal Stem Cells (nMSCs) evade from macrophage mediated phagocytosis via increased CD47 expression and to promote functional recovery by secretion of exosomes and independent cytokines. The increased...

Maryland Stem Cell Research Commission Announces $1,351,400 Million in Stem Cell Program Awards

by secretome | Sep 10, 2019 | News, Uncategorized

The Maryland Stem Cell Research Commission (Commission) has approved funding to its first round of fiscal year 2020 recipients for a total of $1,351,400. The Commission has also announced new leadership with the election of a new chair and vice chair to serve for the...

Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium

by Sudhish Sharma | May 22, 2019 | Journals, Uncategorized

Abstract The stem cell field is hindered by its inability to noninvasively monitor transplanted cells within the target organ in a repeatable, time-sensitive, and condition-specific manner. We hypothesized that quantifying and characterizing transplanted cell–derived...

Stem Cell Therapy for Hypoplastic Left Heart Syndrome: Mechanism, Clinical Application, and Future Directions

by Sudhish Sharma | Jul 6, 2018 | Journals, Uncategorized

Abstract Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete...
« Older Entries

Recent Posts

  • Maryland Stem Cell Research Commission Announces $4 Million in Grants to Drive Stem Cell Innovations
  • Secretome Therapeutics Appoints Margot Connor as Board Director and Assembles World-Class Clinical Advisory Board
  • Secretome Therapeutics Appoints Deepa Prasad as Chief Financial Officer
  • Neoprogen is now Secretome Therapeutics, in alignment with the company’s focus in revolutionizing cell therapy via neonatal cardiac progenitor cells (nCPCs) and their respective secretomes 
  • NeoProgen receives approval from U.S. FDA for a Phase I Study of The Safety And Early Efficacy of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) In Chronic Ischemic Heart Failure
  • Facebook
  • Twitter
  • Instagram
© 2022 Secretome | Reinecke-Design.com